Related Experiment Videos
Anti-tuberculous therapy and acute liver failure
1Institute of Liver Studies, King's College Hospital, London, UK.
Lancet (London, England)
|March 4, 1995
Summary
Tuberculosis drug toxicity is a growing concern. Four cases of severe liver failure highlight the need for careful monitoring of liver function during anti-tuberculosis treatment.
Area of Science:
- Hepatology
- Infectious Diseases
- Pharmacology
Background:
- Rising tuberculosis incidence increases patient exposure to hepatotoxic drugs like isoniazid, rifampicin, and pyrazinamide.
- Fulminant hepatic failure (FHF) is a severe, often fatal complication of drug-induced liver injury (DILI).
- Prompt recognition and management of DILI are critical, especially in the context of tuberculosis treatment.
Observation:
- Four cases of FHF were observed in patients undergoing anti-tuberculosis therapy.
- Hepatotoxicity was attributed to isoniazid, rifampicin, or a combination of both drugs.
- These incidents underscore the potential severity of DILI in this patient population.
Findings:
- The observed cases demonstrate a link between specific anti-tuberculosis drugs and the development of FHF.
- The increasing incidence of tuberculosis correlates with a higher risk of drug-induced liver injury.
- Current treatment guidelines may require re-evaluation regarding liver function monitoring.
Implications:
- Stricter adherence to and review of existing guidelines for liver function tests are crucial.
- Enhanced vigilance for hepatotoxic reactions during anti-tuberculosis therapy is warranted.
- Early detection and intervention can potentially mitigate the risk of fatal hepatic outcomes.